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Abstract 
Natural killer (NK) cells are a population of innate type I lymphoid cells essential for 
early anti-viral responses and are known to modulate the course of humoral and cellular-
mediated T cell responses. We assessed the role of NK cells in allogeneic CD8 T cell-mediated 
responses in an immunocompetent mouse model across an MHC class I histocompatibility 
barrier to determine its impact in therapeutic clinical interventions with polyclonal or 
monoclonal antibodies (mAbs) targeting lymphoid cells in transplantation. The administration of 
an NK cell depleting antibody to either CD8 T cell replete or CD8 T cell-depleted naïve 
C57BL/6 immunocompetent mice accelerated graft rejection. This accelerated rejection response 
was associated with an in vivo increased cytotoxic activity of CD8 T cells against bm1 
allogeneic hematopoietic cells and bm1 skin allografts. These findings show that NK cells were 
implicated in the control host anti-donor cytotoxic responses, likely by competing for common 
cell growth factors in both CD8 T cell replete and CD8 T cell-depleted mice, the latter 
reconstituting in response to lymphopenia. Our data calls for precaution in solid organ 
transplantation under tolerogenic protocols involving extensive depletion of lymphocytes. These 
pharmacological biologics with depleting properties over NK cells may accelerate graft rejection 
and promote aggressive CD8 T cell cytotoxic alloresponses refractory to current 
immunosuppression. 
Introduction 
Natural killer (NK) cells are a population of granular lymphoid cells phenotypically 
characterized by expression of NK1.1 or DX5 and the lack of CD3 and T cell receptor in 
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C57BL/6 mice (B6 mice). 
1,
 
2
 These bone marrow-derived innate cells have evolved to attack and 
kill viral infected and transformed cells in a non-MHC restricted manner without the need of 
prior sensitization. A balance of signals orchestrated through inhibitory and activating receptors 
on NK cells interacting with MHC class I and non-MHC molecules expressed on target cells 
triggers NK cell function. This array of germline-encoded inhibitory and activating receptors 
detects alterations in the molecular composition of the target cells due to infection, malignant 
transformation or cellular stress, instructing NK cells to respond to altered self. 
1, 3,
 
4,
 
5
 
NK cells are also very sensitive to changes on MHC class I expression. Thus, cells 
expressing MHC class I mismatched molecules or autologous cells lacking self-MHC class I 
molecules or cells in which self-MHC class I molecules are down-regulated (missing self-theory) 
become targets for NK cell-mediated cytolysis. 
5,
 
6,
 
7
 Moreover, lethally irradiated F1 hybrid 
mice spontaneously reject parental bone marrow cells (BMCs) or hematopoietic cells, a 
phenomenon against the laws of transplantation named “hybrid resistance”, first described by 
Snell et al., and then confirmed by others. 
8,
 
9,
 
10,
 
11
 
Compelling evidence points to NK cells as regulators of both humoral and cellular 
immune responses in viral infections. In different experimental settings, antibody-mediated NK 
cell depletion modulates the course of CD8 T cell responses by increasing CD8 T cell priming in 
the acute phase of viral infection and enhancing memory responses characterized by an increase 
of central memory T cells (CD44
hi
 CCR7
+
 CD62L
+
). 
12,
 
13
 Similarly, depletion of NK cells leads 
to increased numbers of T follicular helper cells (Tfh) and germinal center B cells, resulting in 
more sustained antibody responses after acute and chronic viral infections. 
14,
 
15
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The role of NK cells in transplant rejection and tolerance is controversial and paradoxical, 
meaning that they can promote either rejection or tolerance. NK cells reject allogeneic bone 
marrow cells 
2,
 
16
 and participate in the rejection of solid organs. 
17
 NK cells also promote cardiac 
allograft vasculopathy (CAV) when parental heart grafts are placed into F1 recipients, in which 
NK cells are the only active mechanism of rejection. 
18
 NK cells may also contribute to prolong 
graft survival and transplant tolerance by eliminating donor-derived antigen-presenting cells 
(APC) and limiting the direct pathway of antigen presentation and T cell priming in draining 
lymph nodes. 
19,
 
20
 
NK cells can also modulate CD8 T cell-mediated graft rejection downregulating CD8 T 
cell homeostatic proliferation in response to lymphopenia by competing for common growth 
factors, such as interleukin (IL)-15. 
21
 Moreover, the population of NK cells expressing low 
rather than high levels of CD27 has been shown to promote allograft survival by limiting the 
homeostatic proliferation and expansion of interferon-γ–producing memory CD8+ T cells under 
costimulatory blockade. 
22
 
In this study, our aim was to address whether NK cells could modulate CD8 T cell-
mediated response in an immunocompetent mouse model of alloreactivity across an MHC class I 
barrier in which rejection is mainly mediated by CD8 T cells and determine its effect in 
therapeutic interventions involving depletion of NK and/or CD8 T cells. 
23,
 
24,
 
25
 Herein, we 
provide evidence that the removal of NK cells (CD3
-
DX5
+
 population and within this, the 
DX5
+
NKp46
+
 subpopulation) accelerated skin graft rejection in immunocompetent B6 recipients 
in both CD8 T cell replete and CD8 T cell-depleted recipients. These findings revealed that NK 
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cells regulate allogeneic CD8 T cell responses to skin allografts when stimulated through the 
direct pathway of antigen presentation not only in immunocompetent recipients, but also in CD8 
T cell-depleted recipients. 
Results 
Naïve NK cells regulate CD8 T cell-mediated rejection of allogeneic hematopoietic target 
cells in vivo in immunocompetent recipients 
To determine whether NK cells regulate the course of graft rejection in 
immunocompetent mice, we chose an experimental mouse model in which donor and recipient 
differed in K
b
 allele (bm1 donor to B6 recipient). 
26
 In this transplant setting, alloreactive effector 
CD8 T cells activated through the direct pathway of antigen presentation are the main mediators 
of rejection. 
23
 
In order to confirm the role of CD8 T cells in targeting bm1 alloantigen, 
carboxyfluorescein succinimidyl ester (CFSE)-labeled bm1 splenocytes were adoptively 
transferred intravenously (i.v.) into B6 recipients that were depleted of either NK cells or CD8 T 
cells. In un-manipulated hosts, there was a gradual clearance of donor bm1 cells (Figure 1); 
however, in mice depleted of CD8 T cells no cytolytic activity against bm1 target cells was 
observed 5 days post-transfer (Figure 1). The cytotoxic activity in this group eventually began to 
recover in both spleen (Figure 1A) and in peripheral lymph nodes (pLNs) (Figure 1B), which 
was likely due to the declining antibody concentration in the periphery and reconstitution of the 
CD8 T cell compartment through thymic output and peripheral homeostatic proliferation in 
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response to lymphopenia. Interestingly, the depletion of NK cells led to an increased clearance of 
CFSE-labeled bm1 cells at day 5 after adoptive transfer compared to isotype-treated control in 
spleen and pLNs (Figure 1) such that bm1 cells were practically undetectable by day 15 in either 
spleen (Figure 1A) or pLNs (Figure 1B). 
Taken together, these data confirm that CD8 T cells are the major immune cell population 
involved in the recognition and clearance of cells bearing the K
bm1
 alloantigen in this setting. 
Furthermore, consistent with other studies, NK cells appeared to hamper cytotoxic T lymphocyte 
(CTL)-mediated clearance of bm1 cells, suggesting a role for NK cells in modulating CD8 T cell 
responses to alloantigen. These findings prompted us to analyze in more detail the role of NK 
cells in a more relevant mouse model of skin allotransplantation across an MHC class I 
mismatched barrier in immunocompetent recipients. 
NK cell depletion accelerates skin graft rejection across an MHC class I histocompatibility 
barrier in immunocompetent mice 
We designed an experimental approach to evaluate the relevance of the above mentioned 
observations and to assess the outcome of skin graft survival in the context of 
immunosuppressive depleting regimens targeting either CD8 or NK cells. This reflects a 
particular scenario of clinical interventions such as, for example, immunosuppressive regimens 
based on thymoglobulin or anti-CD52 antibody therapy (alemtuzumab) with depleting activity 
on lymphoid cells. 
27,
 
28
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As shown in Figure 2A, depletion of NK cells at the time of transplantation accelerated 
bm1 skin graft rejection in B6 recipients (median survival time (MST): 12 days) compared to 
isotype-treated controls (MST: 15 days) (p<0.0001). This suggests that NK cells regulate CD8 T 
cell-mediated rejection in immunocompetent recipient mice. Interestingly, depletion of NK cells 
together with CD8 T cells also significantly accelerated bm1 skin graft rejection in B6 
immunocompetent recipients compared to CD8 T cell-depleted B6 recipients (MST: 20 days 
versus 26 days, p<0.0001) (Figure 2B). 
Figure 2C and 2D show representative macroscopic and microscopic photographs of skin 
bm1 allografts at day 13 and day 21 post-transplantation (post-Tx, respectively. Bm1 skin 
allografts transplanted to B6 recipients were rejected with an MST of 12 days in NK cell-
depleted mice whereas bm1 grafts remained intact in isotype control-treated mice at this time, 
although they were eventually rejected (MST: day 15 post-Tx). Macroscopic signs of rejection 
and histopathological lesions were clearly detectable in NK cell-depleted recipients and in anti-
NK1.1 plus anti-CD8 T cell-depleted B6 mice, at days 13 and day 21 post-transplantation, 
respectively (Figure 2C and 2D). 
Moreover, our work confirms previous evidences supporting the lack of alloantibody 
response against H-2K
bm1
 class I conformational epitopes in C57BL/6 recipients, 
23
 as either no 
detectable Tfh expansion (CD4
+
CXCR5
+
PD-1
+
) cells or germinal center formation 
(B220
+
GL7
+
Fas
+
) or host anti-donor humoral response was seen, as shown in supplementary 
figure 1. 
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Overall, the data indicate that naïve or homeostatically dividing NK cells regulate the 
alloreactive cytotoxic response of CD8 T cells in CD8 T cell replete and CD8 T cell-depleted 
mice, respectively. 
NKT cell and NK cell expansion in draining lymph nodes is associated with ongoing 
alloreactive CD8 T cell-mediated responses and graft rejection 
We first monitored the effectiveness of the depleting NK cell therapy at day 13 and day 
21 post-Tx, which corresponded with the time points around which rejection occurred in NK 
cell-depleted and in CD8/NK1.1 cell-depleted B6 mice, respectively. The population of NKT 
cells (DX5
+
 CD3
+
), a priori susceptible to depletion by anti-NK1.1 antibody, did not show any 
significant reduction in cell number compared to isotype-treated control group in either draining 
or non-draining lymph nodes at any of the two time points evaluated (day 13 post-Tx, Figure 3, 
upper left panel and day 21 post-Tx, Figure 3, upper right panel). It is noteworthy that NKT cells 
increased significantly in draining compared to non-draining pLNs at day 13 post-Tx in isotype-
treated mice close to rejection and in NK cell-depleted mice undergoing rejection, respectively 
(Figure 3, upper left panel). There was also a significant increase in NKT cell numbers at day 21 
post-Tx in CD8 T cell-depleted mice near the time of rejection and in CD8/NK1.1 cell-depleted 
mice undergoing rejection (Figure 3, upper right panel). However, there was no significant 
difference in the number of NKT cells between treatment groups in either non-draining or 
draining pLNs at day 13 and day 21 after Tx (Figure 3, upper left and right panels). These data 
show that NKT cells expand in the draining pLNs during graft rejection. 
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NK cells (DX5
+ 
CD3
-
) exhibited a significant reduction in cell numbers in draining pLNs 
after depletion with anti-NK1.1 mAb compared to isotype control at day 13 and day 21 post-Tx, 
but did not completely eliminate this cell population (Figure 3, middle left and right panels). The 
most sensitive NK cell population to antibody-mediated depletion was, however, the NK cell 
population co-expressing DX5 and NKp46 surface markers. Once eliminated from the periphery 
at day 13 post-Tx (Figure 3, lower left panel), the rate of repopulation was slow and the absolute 
counts were still profoundly reduced at day 21 post-Tx (Figure 3, lower right panel). 
Both subsets of NK cells (DX5
+
CD3
- 
and DX5
+
NKp46
+
) expanded in draining compared 
to non-draining pLNs in isotype-treated control at day 13 after transplantation. NK cell numbers 
also increased significantly, probably as a result of active proliferation or recruitment in draining 
compared to non-draining pLNs at day 13 and day 21 post–Tx in CD8 T cell-depleted mice 
(Figure 3, middle and lower left and right panels) Furthermore, the number of NK cells was 
increased in the draining pLNs of CD8 T cell-depleted mice compared to the isotype-treated 
group at both day 13 post-Tx (Figure 3, middle and lower left panels) and at day 21 post-Tx 
(Figure 3, middle and lower right panels). 
Our data highlighted that NK cells increased in cell numbers after CD8 T cell depletion, 
taking advantage of the open space left by CD8 T cells, preferentially in draining pLNs where 
the allogeneic immune response is occurring. 
Globally, these findings are in favor of the notion that NK cells compete with CD8 T 
cells for space in pLNs and exploit their niche. Moreover, NK cells, and in particular NKp46 
expressing cells, represent the most likely effector innate cells involved in the regulation of 
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allogeneic CD8 T cell-mediated responses stimulated through the direct pathway of antigen 
presentation. 
Effective CD8 T cell depletion and CD4 and CD8 peripheral expansion of naïve and 
memory type T cells in draining lymph nodes 
We next evaluated the effectiveness of CD8 T cell-specific depletion with anti-CD8 mAb 
treatment. 
29
 This depleting therapy was very effective because the absolute cell counts dropped 
profoundly after the administration of two doses of anti-CD8 depleting antibody, as assessed in 
draining and non-draining lymph nodes at day 13 post-Tx (Figure 4, upper left panel). The 
absolute counts of CD8 T cells were still very low at day 21 post-Tx (Figure 4, upper right 
panel), although an incipient recovery was already detectable at that time point, which was 
significantly higher in draining than in non-draining pLNs. Despite the low number of CD8 T 
cells observed at day 21 post-Tx, the frequency of alloreactive cells recognizing bm1 
histoincompatible antigens was sufficient to initiate skin graft rejection in NK/CD8 cell-depleted 
B6 mice (Figure 2B), whereas the presence of NK cells delayed rejection of bm1 skin grafts in 
CD8 T cell-depleted mice (Figure 2B). 
A significant peripheral expansion of CD8 T cells was found in draining compared to 
non-draining pLNs in isotype-treated and anti-NK1.1-treated groups at day 13 post-Tx (Figure 4, 
upper left panel). CD8 T cells also expanded significantly at day 21 post-Tx in draining 
compared to non-draining pLNs in CD8 T cell-depleted and CD8/NK1.1 cell-depleted mice 
(Figure 4, upper right panel). 
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We then analyzed the peripheral clonal expansion of CD4 T cells in non-draining versus 
draining pLNs. We included CD4 T cells in the analysis despite the fact that CD4 T cell 
depletion alone does not change the course of allograft rejection in this mouse model. However, 
it is known that depletion of CD4 T cells synergizes with depletion of CD8 T cells and prolongs 
graft survival beyond that observed in CD8 T cell-depleted mice, a clear indication that 
CD4/CD8 T cell collaboration is necessary to a certain extent for effective CD8 T cell-mediated 
rejection in this model. 
23,
 
24
 The absolute number of CD4 T cells increased in draining pLNs of 
all experimental groups compared to non-draining pLNs at day 13 post-Tx (Figure 4, lower left 
panel). CD4 T cells also expanded significantly after CD8 T cell depletion or in CD8/NK1.1 cell 
depleted mice (Figure 4, right panel). These observations suggest that CD4 T cells were also 
active during graft rejection in draining pLNs of rejecting mice. 
To assess the effect of NK cell depletion on the adaptive immune response to skin 
allografts, the number of alloreactive CD4 and CD8 effector and central memory T cells was 
determined. A significant increase in the number of CD4 and CD8 T effector memory (TEM, 
CD44
high
 CD62L
low
) and T central memory (TCM, CD44
high
 CD62L
high
) cells in isotype and anti-
NK1.1-treated mice was observed at day 13 post-Tx in draining pLNs compared to non-draining 
pLNs (Figure 5A). Alloreactive CD4 T cells and CD8 T cells as well as TEM and TCM cells 
counts increased significantly in draining compared to non-draining pLNs in isotype and NK1.1-
treated groups at day 13 post-Tx and also in CD8 and CD8/NK cell depleted recipient at day 21 
post-Tx (Figure 5A, 5B). 
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This peripheral increase of CD4 and CD8 TEM and TCM cell numbers suggest an active 
process of clonal expansion of both cell populations in response to donor bm1 antigens and T 
cell differentiation towards memory cells with cytotoxic function. 
Enhanced in vivo cytotoxic activity against bm1 target cells after NK cell depletion in naïve 
immunocompetent mice and in CD8 T cell-depleted recipients after skin graft rejection. 
To evaluate the degree of sensitization of B6 recipients after exposure to allogeneic bm1 skin 
grafts at the time of rejection, an in vivo cytotoxic assay was implemented. Thus, at day 13 post-
Tx, NK cell-depleted B6 recipients efficiently killed CFSE-labeled allogeneic bm1 splenocytes 
in the spleen in 24 hours, whereas the other groups did not exhibit any remarkable cytotoxic 
activity (Figure 6A, upper left panel). In the peripheral lymph nodes, however, isotype-treated 
control mice showed evidence of presensitization and cytotoxic activity to some extent, although 
they rejected a few days later (Figure 6A, upper right panel). 
At day 21 post-Tx, NK/CD8 cell-depleted B6 recipients showed strong sensitization with 
high cytotoxic activity against bm1 target cells in spleen compared to CD8 T cell-depleted B6 
mice (Figure 6B, lower left panel). Some residual cytotoxic activity was still present in sensitized 
isotype-treated B6 mice and NK cell-depleted mice that had already rejected their grafts two 
weeks previously. This observed cytotoxic activity in the spleen was similar and correlated well 
to that recorded in peripheral lymph nodes (Figure 6B, lower right panel). 
We performed an experiment at the early time point after bm1 skin grafting to assess the 
frequency of bm1 antigen specific CD8 T cells in draining compared to non-draining lymph 
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nodes using the CD107a degranulation assay. 
30
 Depletion of NK cells led to a modest increase 
of the frequency of CD8 T cells expressing CD107a responding to alloantigen compared to 
isotype-treated mice. This slight increase in CD8
+
CD107a
+
 T cells detected in draining lymph 
nodes is in line with the claim of a low frequency of T cells responding to bm1 antigens (Figure 
7). 
Globally, these data reinforce the notion that NK cells modulate CD8 T cell cytotoxic 
responses against class I MHC mismatched target cells because, in their absence, cytotoxic 
responses were more aggressive. 
DISCUSSION 
The purpose of this work was to assess the role of host NK cells in the regulation of CD8 T cell 
mediated responses stimulated through the direct pathway of antigen presentation. 
23,
 
24,
 
25,
 
39
 In 
this mouse model, alloreactive host CD8 T cells recognize directly unprocessed MHC class I 
mismatched K
bm1
 antigen, whereas alloreactive host CD4 T cells are activated by donor and host 
dendritic cells (DCs) that shared MHC class II presenting donor K
bm1
-derived peptides through 
the indirect pathway of antigen presentation. 
25
 The frequency of alloreactive CD4 T cells 
recognizing allogeneic peptides is very low, which is translated into limited IL-2 help to 
alloreactive CD8 T cells. 
39
 bm1-specific CD4
+
 T helper cells can see a peptide derived from the 
K
bm1
 molecule encompassing the three mutations when presented by MHC class II molecules on 
donor/host APCs. Despite this low frequency of alloreactive CD4 T cells, they can synergize 
with alloreactive CD8 T cells contributing to some extent to the process of rejection across an 
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MHC class I mismatched barrier. 
23,
 
24,
 
39
 In this experimental approach, the host anti-donor 
humoral immune response against bm1 alloantigens does not contribute to the rejection response 
because MHC class I K
bm1
 in B6 mice does not trigger an alloantibody response. This was in line 
with an absolute lack of germinal center formation and CD4 Tfh cell expansion observed in this 
setting (supplementary figure 1). 
Herein, we provide evidence that innate NK cells play an essential role in delaying CD8 
T cell alloreactive responses as depletion of NK cells accelerates bm1 skin graft rejection in CD8 
T cell replete and in CD8 T cell-depleted B6 immunocompetent mice. 
This immune regulatory behavior of NK cells controlling CD8 T cell-mediated immunity 
may have evolved to prevent aggressive cytolytic responses against infected cells in the acute 
phase of viral infection to attenuate excessive tissue damage and the subsequent 
immunopathology. Most of the preliminary evidence on the role of NK cells regulating anti-viral 
CD8 T cell responses come from the LCMV model in which using different strains of virus and 
dosing, it is possible to recreate models of acute infection and chronic infection. 
40,
 
41
 NK cells 
can directly target CD8 T cells for elimination in a perforin- NKG2D-dependent manner or 
indirectly through the removal of mature DCs or viral-infected APCs, thus limiting costimulatory 
signals leading to attenuation of CD4 T cell help to CD8 T cells. 
42
 In the absence of NK cells, 
viral infection triggers CD8 T cell priming that enhances memory T cell responses, leading to an 
increase of the frequency of antigen-specific T cells. T cell differentiation is biased towards 
central memory T cells. 
13
 NK cells can act as rheostats, regulating CD4 T cell help to anti-viral 
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CD8 T cells for the control of viral persistence and the fatal consequences of an intense acute 
immune response to viral infection, preventing the associated immunopathology. 
43
 
In the field of transplantation, previous reports have provided some preliminary evidences 
on the modulatory role of NK cells in allogeneic CD8 T cell responses. Zecher et al. showed that 
the adoptive transfer of syngeneic T cell-enriched splenocytes into immunodeficient Rag2 
gamma chain KO (NK cell deficient) recipients repopulate the peripheral CD8 T compartment 
quicker and 8-fold more CD8 T cells were recovered compared to Rag KO (NK cell sufficient) 
recipients. Similar results were observed in wild type mice depleted of both CD4/CD8 T cells 
compared to NK/T-cell depleted WT mice. 
21
 As opposed to Zecher et al., we could not prove 
that the removal of NK cells conferred an advantage to CD8 T cells to recover quicker and to a 
greater extent. In our transplant setting, CD8 T cells recovered after depletion to the same extent 
in NK sufficient as in NK-cell depleted mice, meaning that NK cell depletion did not alter the 
recovery of the total CD8 T cell numbers. Instead, NK cells exploited the CD8 T cell niche and 
expanded at day 21 post-Tx intensively in non-draining and draining lymph node, particularly in 
CD8 T cell-depleted mice. Interestingly, NK cells also expanded significantly at day 13 post-Tx 
in draining pLNs of isotype-treated control despite the presence of normal CD8 T cell numbers. 
To reconcile these results and to account for the quicker recovery of CD8 T cells in 
immunodeficient Rag 2 KO mice and also in CD4 and CD8 T cell-depleted immunocompetent 
recipients, one can postulate that CD8 T cells recovering under homeostatic conditions in 
response to lymphopenia repopulate a peripheral compartment in which CD4 T cells were also 
depleted, whereas in our experiments, the CD4 T cell compartment was intact. It is known that, 
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in the absence of either CD4 or CD8 T cells subpopulations, the open niche left by one 
population can be occupied by the other population and vice versa in such a manner that the total 
number of T cells remains similar to that present in normal mice. In other words, these two T cell 
populations share common resources and can partially invade each other’s niches. Cell loss of 
one cell type can be compensated by the other population. 
44,
 
45
 
For the interpretation of our observations, we should consider two distinct scenarios 
because MHC class I mismatched skin grafts are rejected in our experimental setting in two 
different situations: CD8 T cell sufficient and CD8 T cell-depleted recipients undergoing 
homeostatic CD8 T cell repopulation. 
In CD8 T cell sufficient mice, at day 13 post-Tx, the mechanism of action of NK cells 
may be mediated through the elimination of donor-derived DCs migrating to draining lymph 
nodes. This effect would lead to attenuation of the direct pathway of antigen presentation as 
shown by others. 
19,
 
20,
 
46
 Yu et al., compared alloantigen-driven T cell homeostatic proliferation 
in lymphopenic environments of immunodeficient mice after allogeneic skin graft transplantation 
between Rag2 deficient (NK sufficient) and Rag2/gamma chain double-deficient (NK deficient) 
mice adoptively transferred with syngeneic T cells. These authors found that deficiency in NK 
cells increased T cell proliferation and accelerated allograft rejection, whereas in NK cell 
sufficient mice, NK cells induced their immunomodulatory function by killing donor-derived 
dendritic cells that migrated to secondary lymphoid organs, leading to enhanced allograft 
survival. 
19
 These findings are coincident with those reported by Laffont et al., who also provided 
evidence for the role of NK cells recruited to the draining lymph nodes in the inhibition of the 
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alloreactive T-cell activation through a perforin-mediated killing of donor-derived allogeneic 
dendritic cells. 
20
 
In CD8 T cell-depleted mice undergoing homeostatic T cell repopulation, at day 21 post-
Tx, the role of donor derived DC is likely to be negligible because of the gradual decay of this 
passenger leukocyte population from the graft. In this scenario, NK cells may delay CD8 T cell-
mediated rejection for their ability to compete with the alloreactive CD8 T cells dividing in 
recipients devoid of CD8 T cells. In favor of this notion is that NK cells expanded in draining 
pLNs of CD8 T cell-depleted recipients at that time point, competing with the alloreactive CD8 
T cells proliferating in response to bm1 alloantigens and homeostatically to lymphopenia, as well 
as with other T cells of the non-alloreactive repertoire. NK cells and CD8 T cells respond to 
similar cytokines (IL-2 and IL-15) for peripheral expansion, and therefore cross-competition for 
these common resources cross-regulate the ability of each population to survive, differentiate and 
proliferate homeostatically in response to lymphopenia. 
47,
 
48,
 
49
 
Newly generated cells (recent thymic emigrants and peripheral cell division) compete in 
the immune system with resident cells for survival. 
44
 Sometimes one population prevents other 
population from occupying a particular niche and from exploiting the resources there 
(interference competition). In other occasions, and more often, different populations may have 
common needs for resources present in the niche, which is in limited supply (exploitation 
competition). 
44
 The CD8 T cell independent niche can, however, be invaded by other cells, such 
as NK cells, an example of exploitation competition, which is in agreement with our results. This 
NK cell exploitation of the CD8 T cell niche may account for the delay of graft rejection. Our 
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data in this sense is in agreement with that reported by Zecher´s work using immunodeficient 
and T cell-depleted immunocompetent recipients who provided evidence in favor of the role of 
NK cells in modulating CD8 T cell responses, not by killing homeostatically proliferating T 
cells, but by competing for T cell growth factors. 
21
 Our findings suggest that this competition for 
common resources may provide an advantage to NK cells that would reduce the availability of 
these cytokines to the alloreactive repertoire of CD8 T cell reacting against bm1 antigens. 
Therefore, reaching the threshold frequency of alloantigen specific CD8 T cells necessary to 
initiate rejection would take longer and consequently graft rejection would be delayed. 
An alternative means for the control of CD8 T cell responses is the direct killing of 
activated CD8 T cells upon upregulation of NKG2D ligands 24-48 hours. Rabinovich et al. 
proved that syngeneic IL-2 activated NK cells can detect altered self-structures on activated CD8 
T cells, not present in resting T cells. These changes in the molecular composition of activated 
CD8 T cells make them susceptible to NK cell-mediated killing by a NKG2D- and perforin-
dependent mechanism. 
50
 
This in vitro NK cytolytic activity is unlikely to occur in vivo because there are 
mechanisms of shielding T cells to prevent their destruction by NK cells, as demonstrated on 
activated CD4 T cells expressing Qa-1 that interact with inhibitory NKG2A NK receptor. This 
interaction confers CD4 T cells with resistance to NK cell-mediated lysis. 
51
 Another example of 
this shielding applies also to CD8 T cells expressing CD48 that inhibit NK cells through 
interaction with 2B4 (CD244). 
52,
 
53
 We found no evidence that NK cells were regulating the size 
Ac
ce
pte
d M
an
us
cri
pt
 
21 
of the CD8 T cell pool, as shown in figure 4A, by killing activated alloreactive CD8 T cells 
because CD8 T cell counts were not affected in the absence of NK cells. 
Conversion from naïve to memory T cell phenotype occurs in response to rapid 
homeostatic T cell proliferation in immunodeficient mice adoptively transferred with syngeneic 
splenocytes or in T cell-depleted immunocompetent recipients. 
54
 Homeostatic proliferation in 
response to lymphopenia is driven by TCR interaction with peptide-MHC on APCs and 
cytokines, such as IL-7 and IL-15. 
55
 We found that the alloreactive CD8 T cell response in 
draining pLNs was associated with a significant conversion of naïve to memory type cells 
(central memory and effector memory) and increased proliferation in both CD8 T cell replete 
(only responding to bm1 antigens at day 13 post-Tx) and CD8 T cell depleted mice (responding 
to bm1 antigens and to lymphopenia at day 21 post-Tx). NK cell depletion did not modify 
significantly the rate of conversion or memory type cell counts. 
Although a priori unexpected, no significant changes were seen in CD8 T cell numbers in 
the draining lymph nodes of grafts undergoing rejection.  To account for this, one possibility is 
that depletion of NK cells led to only a modest increase of the frequency of CD8 T cells 
expressing CD107a responding to alloantigen compared to isotype-treated mice, and this subtle 
change was not reflected in the total CD8 T cell counts. Secondly, the time point at which the 
experiment was analyzed coincided with the initiation of graft rejection and part of the antigen-
specific response may have already become effector and migrated to the graft as effector CTLs. 
One caveat from the use of anti-NK1.1 antibody for NK cell depletion is that it may also 
deplete NKT cells. Therefore, modulation of the immune response after administering anti-
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NK1.1 mAb might be assigned in part to depletion of NKT cells, which are also known to 
exhibit immunoregulatory functions. However, we showed that NKT cells were not reduced 
upon anti-NK1.1 antibody administration, which supports a role for NK and not NKT cells in 
modulating rejection in this setting. NKT cell may have persisted despite anti-NK1.1 mAb 
administration owing to a rapid recovery through thymic output or peripheral reconstitution or 
because decreased susceptibility to depletion attributable to the fact that NKT cells express 
intermediate levels of NK1.1 receptor. This result is in agreement with a report using a 
transgenic mouse model expressing constitutively soluble anti-NK1.1 antibody (clone PK136). 
In this mouse model, NK cells were efficiently eliminated, whereas NKT cell numbers were 
maintained and not affected by the chronic presence of the antibody. 
56
 
The DX5
+
CD3
-
 population of NK cells also exhibited resistance to depletion to some 
degree because anti-NK1.1 depleting therapy did not achieve complete elimination of this 
population in pLNs. The resistance of NK cells (DX5
+
CD3
-
) as opposed to the susceptibility of 
NKp46 cells to depletion makes more likely that the latter is endowed with the capacity to 
modulate CD8 T cell-mediated allogeneic responses in this model. However, both NKp46 cells 
as well as NK cells (DX5
+
CD3
-
) exhibited a competitive advantage over CD8 T cells and 
exploited the CD8 T cell niche when proliferating in draining pLNs, particularly in CD8 T cell-
depleted recipients in the close proximity to rejection. 
Evidence supporting a role for NKT cells in allograft rejection is scarce, with most 
reports relating to their ability to support the induction of tolerance. 
57
 This NKT cell activation, 
along with proinflammatory molecules secreted during graft rejection, may enhance their 
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functional activity in such a manner that can provide an alternative source of help to the rejection 
process, particularly when the major effector T cells, that is, CD8 T cells, are depleted. Similarly 
to NK cells, NKT cells expanded significantly in CD8 replete and CD8 depleted in NK sufficient 
mice in close proximity to rejection. The association of NKT cell expansion with ongoing 
rejection favors the notion that these cells may also play a role helping alloreactive CD8 T cells 
to compensate for their low frequency, which is insufficient for the initiation of graft rejection. 
Indeed, according to some reports NKT cells represent potent helper cells for DC-dependent 
CTL priming. 
58
 
The simultaneous depletion of NK cells and T cells may be undesirable in transplant 
recipients because of homeostatic division in response to lymphopenia converts the naïve 
phenotype of T cells into memory-like phenotype. 
54
 These T cells repopulating the peripheral 
compartment precipitate allograft rejection and resist protocols for tolerance induction. 
59
 Our 
data calls for precaution in solid organ transplantation under tolerogenic protocols involving 
extensive depletion of lymphocytes or leukocytes with agents such as ATG or alemtuzumab 
(anti-CD52 mAb) with partial depleting properties over NK cells. The global immunotherapeutic 
interventions, particularly with polyclonal antibodies against lymphoid cells that target NK cells 
secondarily, may accelerate graft rejection and promote aggressive CD8 T cell cytotoxic 
responses when proliferating in response to lymphopenia because these emerging T cells 
proliferating under homeostatic conditions are refractory to current immunosuppression. 
Ac
ce
pte
d M
an
us
cri
pt
 
24 
Material and methods 
Mice 
Eight- to 12-week-old female C57BL-6J (B6, H-2K
b
, Janvier Labs) and B6.C-H-2
bm1-By
 mice 
(H2-K
bm1
, hereafter bm1 mice) were bred in our facility and used for the experiments described 
in this work. The Animal Welfare Committee of the University of Alcala de Henares (Madrid) in 
accordance with the European Guidelines for Animal Care and Use of Laboratory Animals 
approved all experiments with rodents. 
Antibodies for in vivo use 
Hybridoma cell lines secreting anti-NK.1.1 (clone PK136, mouse IgG2a) or anti-CD8 (clone 2.43, 
rat IgG2b) mAbs were grown in serum-free medium (SFM) (Thermo Fisher Scientific) 
supplemented with IgG-depleted fetal calf serum (FCS) (less than 1%) in spinner flasks. 
29
 Cell 
culture supernatants were pre-filtered, purified by affinity chromatography using a protein G-
Sepharose column, dialyzed against phosphate-buffered saline (PBS) and subsequently filtered 
through 0.45-μm. Purified antibodies for in vivo use were stored frozen in PBS at a concentration 
of 1 mg/ml. Mouse IgG2a (clone MG2a-53) and rat IgG2b (RTK4530) were used as isotype 
control mAbs  for in vivo use. 
We established four different groups according to the following experimental set up: 
Group I: Isotype control, mixture of mouse IgG2a and rat IgG2b; Group II: Selective ablation of 
mouse NK cells with anti-NK1.1 mAb (clone PK136); Group III: Depletion of CD8 T cells with 
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anti-CD8 mAb (clone 2.43) and Group IV: depletion of CD8 T cells and NK cells with anti-CD8 
plus anti-NK1.1 mAb. All groups received 1 mg intraperitoneally of each mAb at the time of 
transplantation and at day 7 post-transplantation. 
Antibodies for flow cytometry 
The following list of flow cytometry antibodies were used for the staining of axillary and 
brachial non-draining and draining peripheral lymph node cell suspensions: CD3 (145-2C11, cat. 
#100321), CD49b (DX5, cat. #108908), CD8 (53-6.7, cat. #100708), CD4 (GK1.5, cat. 
#100432), CD62L (MEL-14, cat. #104421), CD44 (IM7, cat. #103030), CD335 (NKp46, 
29A1.4, cat. #137616) 
31
, B220 (RA3-6B2, cat. #103206), CXCR5 (L138D7, cat. #145504) and 
PD-1 (29F.1A12, cat. #135218) mAbs were obtained from Biolegend. T and B activation antigen 
(GL7, cat. # 562967) and Fas (15A7, cat. # 17-0951-82) were purchased from BD Biosciences 
and Thermo Fisher Scientific, respectively. All antibodies used in this study were properly 
titrated to determine optimal dilution to stain 0.5-1×10
6
 cells per tube. Fc receptors were blocked 
by pre-incubating cell suspensions with 2 μg/ml of blocking anti-FcγR mAb (2.4G2) was 
produced and purified in house and used to reduce nonspecific binding before adding the 
specified biotin- or fluorochrome-labeled mAbs. 
32
 Biotinylated antibodies were detected with 
SA-Brilliant Violet 421. Dead cells and debris were excluded from acquisition by propidium 
iodide (PI). Flow cytometry acquisition was carried out on a Cyan 9 cytometer (Beckman 
Coulter, Miami, FL, USA) and data analysis was performed using WinList version 8.0 (Verity 
Software House, Topsham, ME, USA). 
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Allogeneic skin graft transplantation 
Skin graft transplantation was performed following the protocol previously reported. 
33,
 
34
 
Briefly, skin graft beds were prepared on the right lateral side of the thorax in the vicinity of the 
right axillary/brachial draining lymph nodes region of B6 recipient mice under ketamine-
xylazine anesthesia. bm1 tail skin grafts were placed with four stitches and covered with 
terramycin ointment impregnated gauze, which was removed on day 8 post-transplantation (post-
Tx). Signs of onset and progression of rejection, such as dryness, loss of hair, contraction, 
scaling, and necrosis were recorded by visual inspection for a period of time of 40 days, every 
day in the first 20 days and then every other day from day 20 to day 40 after transplantation. Skin 
grafts were considered fully rejected when complete necrosis of the skin graft was observed. 
Host anti-donor specific antibody response 
For the measurement of B6 host anti-donor K
bm1
 humoral immune response, serum samples were 
collected from the different experimental groups at day 13 and 21 after bm1 skin grafting, then 
diluted at (1:10) and incubated for 1 hour with 0.5 × 10
6
 donor type thymocytes. The extent of 
the host anti-donor isotype-specific humoral immune response was determined by evaluating the 
mean fluorescence intensity values of the staining. As positive control, Balb/c skin grafts were 
placed on B6 recipients and the presence of host anti-donor antibodies was measured at day 13 
after transplantation. 
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GM-CSF-mediated bone marrow-derived dendritic cell 
differentiation 
Syngeneic C57BL/6 (B6) and allogeneic bm1 bone marrow cells were harvested from tibiae and 
differentiated with 30 ng/ml murine GM-CSF (PeproTech), as previously described. 
35,
 
36
 Bone 
marrow-derived DC (BM-DC) were finally matured upon overnight exposure to 1 µg/ml LPS 
O111:B4 (Sigma-Aldrich). 
CD107a degranulation assay 
1.5 × 10
5
 of draining and non-draining (axillar and brachial) pLNs were isolated around day of 
rejection from B6 syngeneic or allogeneic bm1 skin grafted mice treated either with isotype 
control or anti-NK1.1 antibody and then were re-stimulated in vitro with 0.5 × 10
5
 of either 
syngeneic (B6) or allogeneic bm1 mature BM-DC. PE-labelled isotype-matched control (clone 
Rtk-275, Biolegend) or PE-conjugated anti-CD107a mAb (clone 1D4B, Biolegend) were added 
to the cell culture and incubated for 1 hour at 37 ºC in 5% CO2 atmosphere. Stimulator and 
responder cells were incubated for four additional hours in the presence of Golgi plug 2 M 
monensin and CD107a degranulation assay was used as a surrogate assay to monitor cytolytic 
function on donor CD8
+
 T cells. 
30
 For the gating strategy, a dump channel was set to include the 
following markers (CD19, CD11b and CD11c). 
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In vivo cytotoxic T lymphocyte (CTL) assay 
Single-cell suspensions were prepared from spleens of bm1 female mice in RPMI 1640 complete 
medium as target cells for the in vivo CTL assay. Target cells were washed twice in D-PBS and 
labeled with CFSE (Molecular Probes) at 1 μM for 10 min at 37 °C. 37 The reaction was stopped 
by adding two volumes of cold RPMI 1640 containing 10% FCS followed by two washes in D-
PBS. 15 × 10
6
 of CFSE-labeled bm1 target cells were i.v. injected to each group of mice at day 
13 and day 21 post-skin graft transplantation. Twenty-four hours later, recipient mice were 
euthanized and the specific killing of bm1 target cells was calculated as the absolute number of 
CFSE-labeled bm1 splenocytes remaining 24 hours after cell transfer in host spleen and 
peripheral lymph nodes (pLNs). 
38
 
Histology 
Allogeneic and syngeneic skin grafts samples from representative mice of each experimental 
group were fixed in 10% neutral-buffered formalin and conventionally processed. Fixed samples 
were dehydrated through a graded alcohol series before being embedded in paraffin wax 
following conventional processing for histological examination. Microtome Sections (4 µm 
thick) were cut, mounted on glass microscope slides and stained with hematoxylin and eosin. 
Finally, the slides were dehydrated and mounted for histological examination. 
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Statistical analysis 
Collected data was organized in excel worksheets and Prism data tables. Results are expressed as 
mean ± SD or mean ± SEM. For the statistical analysis of normally distributed data, statistical 
significance between non-draining versus draining pLNs was calculated using two-tailed Student 
t test. For the comparison of more than 2 groups, one way ANOVA statistical test was applied. 
Adjustments for multiple comparisons were performed with the Tukey-Kramer comparison test. 
These statistical studies were performed under the conditions of independence of the data, 
normality test (Kolmorogov test) and equal variances among groups (Bartlett´s test). Parametric 
or non-parametric tests were applied accordingly. 
Skin graft survival was calculated by using the Kaplan–Meier life table method and 
statistical analysis for the comparison of the survival curves was performed by the log rank 
(Mantel-Cox) test. The statistical analysis was performed using GraphPad Prism 6.0 software 
(Graphpad Software, Inc., La Jolla, CA). A value of p< 0.05 was considered statistically 
significant. 
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Figure 1: Host NK cells regulate CD8 T cell-mediated cytotoxic responses in vivo against 
bm1 hematopoietic target cells 
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Naïve B6 mice were treated at day 0 and day 7 with 1 mg/mouse of isotype control (red bars), 
anti-NK1.1 antibody (black bars) or anti-CD8 antibody (blue bars). The same day, the three 
groups of mice were injected with CFSE-labeled female bm1 splenocytes (15 × 10
6
 splenocytes). 
The absolute number of bm1 hematopoietic cells remaining in spleen and peripheral lymph 
nodes (pLNs) (inguinal plus axillary and brachial) was evaluated at day 5, 9 and 15 after cell 
transfer. Results are expressed as mean ± SD and the data comes from a pool of two experiments 
with three mice per experimental group.*, p< 0.05; **, p< 0.005; ***, p< 0.0005 were 
considered statistically significant. 
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Figure 2: Depletion of NK cells accelerates bm1 skin allograft rejection in both CD8 T cell 
replete and CD8 T cell-depleted B6 recipients 
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bm1 skin allografts placed on B6 recipients were followed for 40 days after transplantation. 
C57BL/6 recipient mice were treated at day 0 and day 7 with 1 mg of either isotype control or 
anti-NK1.1 depleting antibody (A), or with anti-CD8 mAb or anti-CD8 mAb plus anti-NK1.1 
mAb (B). The survival curve was plotted following the Kaplan–Meier life table method and the 
statistical analysis was performed using the long-rank test. The survival curve is the global result 
of a pool of 6 experiments. Visual macroscopic inspection of the bm1 skin grafts (C) and 
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hematoxylin and eosin (H/E) staining of skin tissue sections (D) of the four experimental groups 
are depicted at day 13 and day 21 post-Tx. bm1 skin graft rejection occurred at day 13 post-Tx in 
NK cell depleted recipients and at day 21 post-Tx in CD8/NK cell depleted recipients few days 
in advance than in isotype control or anti-CD8 T cell depleted mice, respectively. Severe 
rejection of donor bm1 tail skin was accompanied with necrosis of donor epithelium and intense 
dermal mononuclear infiltration. Black dotted ellipse highlights massive necrosis of skin 
epithelium and dermis underneath of donor bm1 skin graft in the tissue section. Statistical 
significance is indicated as follows: *p< 0.05, **p< 0.005, ***p< 0.0005, and ns, non-
significant. 
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Figure 3: NKT cell and NK cell expansion in draining pLNs during the course of graft 
rejection in both CD8 T cell replete and CD8 T cell-depleted recipients 
 
Non-draining and draining axillary and brachial pLN from each experimental group of bm1 skin-
grafted B6 recipients were collected at two time points after transplantation. The absolute 
number of NKT (DX5
+
CD3
+
) cells, non-T NK cells (DX5
+
CD3
-
 cells and DX5
+
NKp46
+
 cells) 
was quantified at day 13 (left side panel) and day 21 (right side panel) post-Tx. Results are 
displayed as mean ± SD. Statistical significance and p value was calculated using unpaired 
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Student's t test for the comparison of means between draining versus non-draining pLN in each 
experimental group. One way ANOVA was applied for the comparison of means among 
experimental groups within non-draining or draining pLNs. The following criterion of statistical 
significance was used: *, p< 0.05; **, p< 0.005; ***, p< 0.0005. These plots display data pooled 
from three independent experiments with three mice per group. 
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Figure 4: Expansion of CD4 T cells and CD8 T cells in draining pLNs of B6 mice after skin 
transplantation across an MHC class I barrier 
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Non-draining and draining axillary and brachial pLNs from each experimental group of bm1-
skin grafted B6 recipients were collected at two time points after transplantation. 
The absolute number of CD8 T cells (upper panels) and the absolute number of CD4 T cells 
(lower panels) at day 13 and day 21 post-Tx is depicted in draining and non-draining lymph 
nodes. Results are displayed as mean ± SD. Statistical significance and p value was calculated 
using unpaired Student's t test for the comparison of means between draining versus non-
draining pLN in each experimental group. The following criterion of statistical significance was 
used: *, p< 0.05; **, p< 0.005; ***, p< 0.0005. These plots display data pooled from three 
independent experiments with three mice per group. 
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Figure 5: Increased of CD8 T cells and CD4 memory type T cell numbers in draining pLNs 
of B6 mice after skin transplantation across an MHC class I barrier 
 
The absolute number of CD8 and CD4 TEM cells at day 13 post-Tx (upper left panel) (A) and 
day 21 post-Tx (upper right panel) (B) and the absolute number of CD8 and CD4 TCM cells at 
day 13 post-Tx (lower left panel) (A) and day 21 post-Tx (lower right panel) (B) is depicted in 
non-draining and draining lymph nodes. Results are displayed as mean ± SD. Statistical 
significance and p value was calculated using unpaired Student's t test for the comparison of 
means between draining versus non-draining pLN in each experimental group. The following 
criterion of statistical significance was used: *, p< 0.05; **, p< 0.005; ***, p< 0.0005. These 
plots display data pooled from two independent experiments. 
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Figure 6: NK cell depletion augmented in vivo CTL activity of skin-grafted sensitized 
allogeneic CD8 T cells against bm1 hematopoietic target cells 
 
bm1 skin-grafted B6 recipients were challenged with CFSE-labeled target bm1 cells at day 13 
(time of rejection for NK cell-depleted group) and day 21 (time of rejection for CD8/NK cell-
depleted group) after Tx. The killing of bm1 hematopoietic target cells was evaluated as the total 
cell counts of bm1 cells remaining in spleen (A) and pLNs (B) 24 hours after i.v. injection of 
15106 of CFSE-labeled bm1 target splenocytes at day 13 and day 21 after Tx. Results are 
displayed from one representative experiment out of two with three mice for each experimental 
group. Results are displayed as mean ± SD. *, p< 0.05; **, p< 0.005; ***, p< 0.0005 were 
considered statistically significant. 
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Figure 7: NK cell depletion increases donor alloantigen specific CD8
+
 T cells expressing 
CD107a. 
 
At the time of rejection initiation in NK-cell depleted mice, 1.5 × 10
5
 cells from non-draining 
and draining pLNs (axillar and brachial) were isolated from syngeneic or allogeneic bm1 skin 
grafted treated either with isotype control or anti-NK1.1 antibody. Then, syngeneic and 
allogeneic lymphocytes were re-stimulated in vitro with 0.5 × 10
5
 allogeneic syngeneic control 
and bm1 allogeneic mature BM-DC per well for 1 hour in the presence of PE-conjugated isotype 
control or PE-conjugated anti-CD107a mAb. Finally, the Golgi plug monensin was added and 
incubated 4 more hours. This figure is a representative experiment of two performed with similar 
results using one mouse /experimental group/experiment. 
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Supplementary Figure 1: Absence of T follicular helper cell (B220
-
CD4
+
CXCR5
+
PD-1
+
) 
expansion and germinal centers (B220
+
GL7
+
Fas
+
) formation during allograft rejection across 
an MHC class I barrier. 
 
T follicular helper and germinal center B cell expansion from draining lymph nodes at day 13 
(A) and day 21 (B) from the different experimental groups of our study are depicted. (C) As 
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positive control for the stainings, B6 recipients were grafted with allogeneic Balb/c skin and Tfh 
cells and germinal center cells were analyzed at day 13 after transplantation. (D) Naïve serum 
and sera from B6 recipient mice transplanted with bm1 skin were collected at days 13 and 21 
after transplantation. A positive control serum from allogeneic Balb/c skin grafted into B6 
recipients was also assayed using donor-type thymocytes. Samples were then incubated with 
donor thymocytes and host anti-donor total IgG humoral immune responses were measured. 
 
 
